Radioiodine treatment of differentiated thyroid cancer related to guidelines and scientific literature
| Autor: | M. Mitjavila, E. Caballero, M.A. Muros, M. Estorch |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Scientific literature Disease 030218 nuclear medicine & medical imaging Iodine Radioisotopes 03 medical and health sciences 0302 clinical medicine Initial risk stratification medicine Humans Thyroid Neoplasms Intensive care medicine Thyroid cancer General Environmental Science business.industry Thyroid General Engineering Thyroidectomy Cancer I-131 Differentiated thyroid cancer medicine.disease Clinical trial medicine.anatomical_structure Practice Guidelines as Topic General Earth and Planetary Sciences Radiotherapy Adjuvant Observational study Dynamic risk stratification Radioiodine treatment business |
| Zdroj: | REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR r-FISABIO. Repositorio Institucional de Producción Científica instname |
| ISSN: | 2253-8089 2253-654X |
| Popis: | In differentiated thyroid cancer (DTC), radioiodine is administered to eliminate residual normal thyroid tissue after thyroidectomy (ablative treatment), to treat residual microscopic disease (adjuvant treatment), and to treat macroscopic or metastatic disease. Currently, treatment of DTC with I-131 is still a matter of controversy due to the absence of prospective clinical trials assessing its benefit in terms of overall survival and recurrence-free interval. The current recommendations of the experts are based on observational retrospective data and on their interpretation of the literature. Pending the results of the prospective trials that are currently underway, the use of I-131 seems to be justified not only in high-risk patients, but also in intermediate-risk and low-risk patients. The guidelines of The American and British Thyroid Association, European and American Societies of Nuclear Medicine, The European Consensus Group and the latest edition of National Comprehensive Cancer Network (NCCN) were considered in drawing up this continuing education document, we also undertook a review of the related scientific literature. (C) 2019 Published by Elsevier Espafia, S.L.U. on behalf of Sociedad Espafiola de Medicina Nuclear e Imagen Molecular. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect